Maddrey discriminant function in alcoholic hepatitis is a critical clinical prognostic tool designed to quantify short-term mortality risk and direct life-saving therapeutic interventions in patients presenting with acute hepatic decompensation secondary to heavy alcohol abuse 1,2,3. First established by Dr. Willis C. Maddrey and colleagues, the discriminant function (DF) mathematically weighs standard laboratory measures of synthetic liver failure and impaired excretory function—specifically prothrombin time prolongation and serum total bilirubin levels—to stratify patients into mild-to-moderate versus severe disease categories 2,3,4. In clinical practice, a modified Maddrey discriminant function score equal to or exceeding 32 defines severe alcoholic hepatitis, a condition historically associated with a 1-month and 6-month mortality rate approaching 30% to 50% without targeted medical management 1,3,4. This objective scoring system guides hepatologists and critical care specialists in selecting candidates for systemic corticosteroid therapy, monitoring early therapeutic response via the Lille model, and evaluating refractory cases for early liver transplantation evaluation 1,2,5.
Etiology & Risk Factors
- Chronic Ethanol Consumption: Ingestion of significant quantities of alcohol over a prolonged duration (typically exceeding 40–80 grams daily in males and 20–40 grams daily in females for over 5 to 10 years) is the fundamental primary etiology 1,3.
- Biological Sex Disparity: Female biological sex is a well-established independent risk factor, demonstrating increased susceptibility to alcohol-mediated hepatic injury at significantly lower cumulative doses and shorter durations of exposure due to differences in gastric alcohol dehydrogenase activity and body fat distribution 3,5.
- Nutritional Status & Malnutrition: Severe protein-calorie malnutrition, common in chronic heavy drinkers, depletes hepatic glutathione stores, impairs cellular antioxidant defenses, and accelerates lipid peroxidation and fibrogenesis 1,5.
- Genetic and Epigenetic Factors: Polymorphisms in genes encoding enzymes involved in ethanol metabolism (such as alcohol dehydrogenase and aldehyde dehydrogenase) as well as patatin-like phospholipase domain-containing protein 3 (PNPLA3) variants modulate individual risk and disease progression 3,4.
- Coexisting Viral Hepatitis & Metabolic Syndromes: Concurrent chronic hepatitis C virus (HCV) infection, non-alcoholic fatty liver disease (NAFLD), or iron overload synergistically amplify hepatic injury and accelerate clinical decompensation 4,7.
Pathophysiology
The pathophysiological cascade underlying severe alcoholic hepatitis is characterized by a potent synergistic combination of direct hepatocellular toxicity, immune-mediated injury, gut-derived endotoxemia, and profound microcirculatory dysfunction 4,6,7. Ethanol metabolism via alcohol dehydrogenase (ADH) and cytochrome P450 2E1 (CYP2E1) generates excessive reactive oxygen species (ROS) and acetaldehyde, leading to mitochondrial dysfunction, lipid peroxidation, and the formation of intrahepatic neoantigens 3,4. Concurrently, chronic alcohol ingestion alters intestinal tight junction proteins, increasing gut permeability and facilitating the translocation of bacterial lipopolysaccharides (LPS) via the portal circulation into the liver parenchyma 5,7.
Lipopolysaccharides bind to Toll-like receptor 4 (TLR4) on resident hepatic macrophages (Kupffer cells), triggering a massive upregulation of pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-$\alpha$), interleukin-1 beta (IL-1$\beta$), and interleukin-6 (IL-6) 4,6. This cytokine storm drives severe systemic inflammation, systemic inflammatory response syndrome (SIRS), and neutrophil recruitment into the hepatic lobules 4. The infiltrating neutrophils release cytotoxic elastases and reactive oxygen species, compounding hepatocyte necrosis and ballooning degeneration 2,3. Concurrently, regenerative capacity is severely hindered by progenitor cell exhaustion and impaired hepatocyte proliferation, culminating in progressive hepatic failure, deep jaundice, hepatorenal syndrome, and coagulopathy 2,4,6.
Clinical Presentation & Classic Clinical Signs
- History & Cardinal Symptoms: Patients classically present with the abrupt onset of fatigue, marked malaise, anorexia, nausea, right upper quadrant or epigastric abdominal discomfort, and recent-onset visible jaundice occurring over a span of days to 2 to 3 weeks following a period of heavy, continuous alcohol intake 2,3,7.
- Physical Examination & Named Clinical Signs: Examination reveals deep mucocutaneous icterus, tender hepatomegaly (due to rapid cellular swelling), signs of chronic liver disease (such as spider angiomata, palmar erythema, Dupuytren contractures, parotid gland enlargement, and gynecomastia in males), shifting dullness indicating ascites, and asterixis or altered mental status if concurrent hepatic encephalopathy has developed 2,4,6.
Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)
| Diagnostic Modality / Test | Expected Clinical & Radiological / Laboratory Finding |
|---|---|
| Gold-Standard Investigation | Transjugular or percutaneous liver biopsy revealing hallmark features: ballooned hepatocytes, Mallory-Denk bodies, intense neutrophilic lobular infiltration, pericellular fibrosis, and megamitochondria. (Biopsy is reserved for cases with diagnostic ambiguity or atypical laboratory profiles). |
| Laboratory Panel | Serum total bilirubin markedly elevated (often greater than 5–10 mg/dL); AST and ALT moderately elevated but characteristically displaying an AST-to-ALT ratio greater than 2:1 (with absolute values rarely exceeding 300 IU/L); elevated international normalized ratio (INR) reflecting synthetic failure; leukocytosis with neutrophilia (often exceeding 15,000–20,000 cells/$\mu$L); and potential azotemia indicating acute kidney injury or hepatorenal syndrome 2,3,6. |
| Imaging / Radiology (X-ray, US, CT, MRI) | Abdominal ultrasound with Doppler evaluation demonstrates diffuse hepatic echogenicity consistent with steatosis or cirrhosis, blunted liver margins, ascites, splenomegaly, and patent portal and hepatic veins to exclude Budd-Chiari syndrome and portal vein thrombosis 2. |
| ECG / Histopathology / Procedural | Diagnostic paracentesis is mandatory upon admission to analyze ascetic fluid cell counts and differentials, ruling out spontaneous bacterial peritonitis (SBP) which can clinically mimic or complicate alcoholic hepatitis exacerbations 6. |
Staging, Classification & Clinical Scoring Systems
| Criterion / Stage / Score Component | Clinical Threshold, Points & Management Implication |
|---|---|
| Modified Maddrey Discriminant Function (mDF) | Calculated via formula: $4.6 \times (\text{Prothrombin Time}_{\text{patient}} - \text{Prothrombin Time}_{\text{control}}) + \text{Serum Bilirubin (mg/dL)}$ (or $3.8 \times (\text{PT}_{\text{patient}} - \text{PT}_{\text{control}}) + \text{Bilirubin ($\mu$mol/L)} / 17.1$). Threshold: $\ge 32$ Implication: Indicates severe alcoholic hepatitis with high 30-day mortality; mandates immediate systemic corticosteroid therapy 1,2,4,6. |
| Model for End-Stage Liver Disease (MELD) Score | Calculated using serum bilirubin, serum creatinine, and INR. Threshold: > 21 Implication: Correlates with severe short-term mortality and identifies patients who benefit from aggressive pharmacological therapy or evaluation for early liver transplantation 4. |
| Glasgow Alcoholic Hepatitis Score (GAHS) | Combines age, serum bilirubin, blood urea nitrogen (BUN), peripheral blood white blood cell count, and prothrombin time. Threshold: $\ge 9$ Implication: Identifies patients with poor prognosis who require specialized inpatient management and intensive care support 2,3. |
| Lille Model Score (evaluated at Day 7) | Calculated dynamically using age, baseline albumin, baseline bilirubin, evolution of bilirubin at day 7, prothrombin time/INR, and renal function. Threshold: $> 0.45$ Implication: Scores $> 0.45$ indicate non-responsiveness to corticosteroids; treatment should be promptly discontinued at day 7 to avoid excess sepsis risks without survival benefit 2,6. |
Differential Diagnosis
| Differential Condition | Distinguishing Clinical, Biochemical & Imaging Features |
|---|---|
| Acetaminophen Toxicity / Drug-Induced Liver Injury (DILI) | History of acute ingestion or medication exposure; aminotransferases (AST and ALT) are typically massively elevated (often exceeding 1,000–3,000 IU/L), in sharp contrast to alcoholic hepatitis where transaminases rarely exceed 300 IU/L with an AST:ALT ratio under 2:1. |
| Acute Decompensated Non-Alcoholic Steatohepatitis (NASH) | Metabolic syndrome risk factors (obesity, type 2 diabetes, dyslipidemia); absence of a history of heavy chronic alcohol consumption; biopsy reveals steatohepatitis without Mallory-Denk bodies or neutrophilic predominance. |
| Acute Viral Hepatitis (Hepatitis A, B, or E) | Positive specific viral serologies (e.g., IgM anti-HAV, HBsAg, IgM anti-HBc, or HEV RNA); marked aminotransferase elevations; absence of chronic alcohol abuse history. |
| Obstructive Jaundice / Choledocholithiasis / Cholangitis | Markedly elevated alkaline phosphatase and gamma-glutamyl transferase (GGT) out of proportion to transaminases; abdominal imaging (ultrasonography, MRCP, or CT) demonstrates extrahepatic or intrahepatic biliary ductal dilatation and potential stone or stricture obstruction. |
Management & Treatment Protocol
- Initial Stabilization & Resuscitation: Admission to an inpatient or intensive care setting for hemodynamic monitoring, correction of electrolyte disturbances (especially hypokalemia, hypomagnesemia, and hypophosphatemia), prevention and management of alcohol withdrawal syndrome using symptom-triggered benzodiazepines (or short-acting lorazepam in advanced cirrhosis), and administration of intravenous thiamine before glucose repletion to prevent Wernicke encephalopathy 2,6.
- First-Line Medical / Pharmacological Therapy (with exact adult dosing): For patients with a modified Maddrey discriminant function score $\ge 32$ (and in the absence of absolute contraindications such as active uncontrolled infection, gastrointestinal bleeding, renal failure, or fungal sepsis), initiate oral prednisolone at 40 mg once daily for 28 days 1,2,4,6. If oral administration is precluded, equivalent intravenous methylprednisolone may be utilized. Re-evaluate clinical response at Day 7 using the Lille score; if the Lille score exceeds 0.45, discontinue corticosteroids immediately due to lack of efficacy and high risk of infectious complications 2,6.
- Nutritional Support & General Measures: Provide aggressive nutritional support targeting 35–40 kcal/kg/day and 1.2–1.5 g/kg/day of protein via enteral nutrition if oral intake is insufficient, as nutritional repletion improves long-term survival and immune function 1,5,6. Absolute, lifelong alcohol abstinence counseling and multidisciplinary addiction team engagement must be initiated during hospitalization 1,2.
- Surgical / Interventional Indications: Early liver transplantation should be considered for highly selected patients with severe alcoholic hepatitis who fail to respond to medical therapy (non-responders with high Lille scores) and meet rigorous multi-disciplinary selection criteria, including lack of severe psychiatric comorbidity and commitment to lifelong sobriety 1,5.
Complications & Prognosis
- Acute Complications: High risk of developing variceal hemorrhage, hepatorenal syndrome (requiring volume expansion and vasoconstrictor therapy such as terlipressin and albumin), hepatic encephalopathy, spontaneous bacterial peritonitis, sepsis, and multiorgan failure 1,4,6.
- Prognostic Indicators & Mortality: Short-term (1-month and 3-month) mortality remains exceptionally high (30%–50%) for patients with severe alcoholic hepatitis meeting Maddrey DF criteria $\ge 32$ 1,3,4. Long-term survival and avoidance of recurrent hepatic decompensation depend almost exclusively on the maintenance of complete, lifelong alcohol abstinence 1.